![Glenn Vraniak](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Glenn Vraniak
Direttore/Membro del Consiglio presso
Apollomics, Inc. (United States)
Profilo
Glenn S.
Vraniak is the founder of Perceptus.
Current job includes Independent Director at Apollomics, Inc. since 2023.
Former jobs include Independent Director at Apollomics, Inc., President at Aprecia Pharmaceuticals Co. from 2011 to 2013, Executive Vice President at GE Capital Transportation Finance from 2000 to 2002, Chief Financial Officer at Prasco LLC from 2003 to 2011, Chief Financial Officer at G&W Laboratories, Inc. from 2014 to 2016, Chief Financial & Accounting Officer at electroCore, Inc. from 2018 to 2019, Principal at Gsv Advisory Services, LLC in 2016, Chief Financial Officer at Inversago Pharma, Inc. from 2022 to 2024, CFO-Autonomous Automotive Technology Division at Valeo SE from 2021 to 2022, and Chief Financial Officer at Evaxion AS from 2019 to 2021.
Education includes undergraduate and MBA from Rutgers Center For Management Development.
Posizioni attive di Glenn Vraniak
| Società | Posizione | Inizio |
|---|---|---|
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Direttore/Membro del Consiglio | 30/03/2023 |
Precedenti posizioni note di Glenn Vraniak
| Società | Posizione | Fine |
|---|---|---|
| APOLLOMICS, INC. | Direttore/Membro del Consiglio | 03/09/2025 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Direttore Finanziario/CFO | 01/07/2024 |
| VALEO SE | Corporate Officer/Principal | 01/04/2022 |
| EVAXION A/S | Direttore Finanziario/CFO | 01/10/2021 |
| ELECTROCORE, INC. | Direttore Finanziario/CFO | 01/04/2019 |
Formazione di Glenn Vraniak
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
39
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Aprecia Pharmaceuticals Co.
 Aprecia Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Manufactures and develops drugs | Health Technology |
Valeo SE
 Valeo SE Auto Parts: OEMProducer Manufacturing Manufactures and sells visibility, powertrain, thermal and driving systems | Producer Manufacturing |
GE Capital Transportation Finance
 GE Capital Transportation Finance Finance/Rental/LeasingFinance Provides customized leases and secured loan | Finance |
Prasco LLC
 Prasco LLC Pharmaceuticals: GenericHealth Technology Manufactures generic drugs | Health Technology |
G&W Laboratories, Inc.
 G&W Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
electroCore, Inc.
 electroCore, Inc. Medical SpecialtiesHealth Technology Develops non-invasive neuromodulation therapies | Health Technology |
Evaxion Biotech A/S
 Evaxion Biotech A/S BiotechnologyHealth Technology Develops novel vaccines | Health Technology |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Health Technology |
Perceptus | |
Rutgers Center For Management Development
 Rutgers Center For Management Development Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gsv Advisory Services, LLC | |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
Apollomics, Inc.
 Apollomics, Inc. Financial ConglomeratesFinance Operates as a biotechnology company that focuses on development of novel medicines for cancer patients | Finance |
